The APPG on Polyendocrine Metabolic Ovarian Syndrome (PMOS) recently brought together parliamentarians, Government officials, NHS England, NICE, clinicians and patient representatives to discuss the next steps following the international name change from Polycystic Ovary Syndrome (PCOS) to PMOS.
The roundtable focused on ensuring that the new name leads to meaningful improvements in care for the millions of people living with PMOS. Discussions covered earlier diagnosis, greater awareness among healthcare professionals and the public, improved NHS coding and data collection, and more coordinated, lifelong care.
Participants agreed that the new terminology better reflects the complex, multisystem nature of the condition, helping to move away from misconceptions that it is solely a reproductive disorder.
The meeting also highlighted the importance of embedding PMOS within national policy, education and clinical practice to improve outcomes and reduce the variation in care experienced across the country.
The APPG looks forward to continuing to work with Government, the NHS, clinicians and patient groups to ensure the name change delivers lasting improvements in diagnosis, treatment and support for everyone affected by PMOS.